0 seconds of 1 minute, 49 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
01:49
01:49
 
  • Mednow (MNOW) reported Q1/23 revenue increased approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year
  • Mednow patient count by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22
  • Reduced costs by 30 per cent, achieved additional cost savings post-Q1’23 to further reduce cash burn
  • Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results
  • Mednow is a healthcare technology company
  • Mednow Inc. (MNOW) opened trading at $0.29 per share

Mednow (MNOW) has released its financial results for the period ending October 31, 2022 (Q1 2023).

In fiscal Q1, revenue increased by approximately 35 per cent Q/Q to $9.7 million, and approximately 1,300 per cent year-over-year

Mednow’s patient count increased by approximately 13 per cent to ~35,000 in Q1’23 versus ~31,000 in Q4’22.

Ali Reyhany, Founder & CEO of Mednow, sat down with Sabrina Cuthbert to discuss the results.

Mednow is a Canadian-based healthcare technology company. Mednow.ca provides virtual pharmacy and telemedicine services, as well as doctor home visits.

Mednow Inc. (MNOW) opened trading at $0.29 per share. 


More From The Market Online
Medicine factory line

Buyout disclosure sends Theratechnologies stock soaring

Future Pak discloses its intention to acquire Theratechnologies (TSX:TH), a biopharmaceutical company focused on oncology and HIV.
Cancer therapy targeting malignant cell

Small-cap cancer therapy innovator raises $20M in flexible funding

Oncolytics Biotech (TSX:ONC), a cancer therapy developer, announces a US$20M financing with institutional investor Alumni Capital.
AI generated stock image

Investing in Canadian medical stocks under $10

Healthcare stocks in Canada are publicly traded companies that operate in various sectors of the healthcare industry.